Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin
Synonyms Bevacizumab + FOLFOX
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Bevacizumab Avastin VEGF Antibody 10 VEGFR Inhibitor (Pan) 33 Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).
Fluorouracil Adrucil 5-FU Chemotherapy - Antimetabolite 14 Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth and is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov).
Leucovorin Wellcovorin Calcium folinate|Calcium citrovorum factor|folinic acid Chemotherapy - Antimetabolite 14 Wellcovorin (leucovorin) is a metabolite of folate that enhances the efficacy of fluoruracil (PMID: 32490554).
Oxaliplatin Eloxatin Diaminocyclohexane Oxalatoplatinum Chemotherapy - Platinum 7 Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity, and is FDA approved for colorectal cancer (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01006369 Phase II Hydroxychloroquine Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Completed USA 0
NCT01910610 Phase III Cetuximab Irinotecan + Panitumumab Panitumumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Capecitabine + Oxaliplatin Cetuximab + Irinotecan Cetuximab + Fluorouracil + Irinotecan + Leucovorin Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (STRATEGIC-1) Recruiting FRA 2
NCT02997228 Phase III Atezolizumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer Recruiting USA 0
NCT01792934 Capecitabine + Oxaliplatin Bevacizumab + Capecitabine + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases (ORCHESTRA) Recruiting 2
NCT05462613 Phase II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Aspirin + Bevacizumab + Capecitabine + Cyclophosphamide + Fluorouracil + Leucovorin + Oxaliplatin + Regorafenib Aspirin + Bevacizumab + Capecitabine + Cyclophosphamide + Fluorouracil + Irinotecan + Leucovorin + Regorafenib Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer (REPROGRAM-02) Not yet recruiting FRA 0
NCT01765582 Phase II Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer Terminated USA 0
NCT04607421 Phase III Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Encorafenib Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer Recruiting USA | ITA | ESP | DEU | CAN | BEL 23
NCT04660812 Phase Ib/II AB680 + AB928 + Zimberelimab Regorafenib AB928 + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab AB928 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin An Open Label Study Evaluating the Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer. Active, not recruiting USA | ITA | FRA | ESP 2
NCT01871571 Phase II Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer Active, not recruiting USA 0
NCT03203525 Phase I Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Doxorubicin + Temsirolimus Study of the NovoTTF-100L System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic Cancer Recruiting USA 0
NCT05480306 Phase II Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin DKN-01 + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin Phase 2 Study of DKN-01 in Colorectal Cancer (DeFianCe) Recruiting USA 0
NCT05253651 Phase III Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03) Recruiting USA 1
NCT03414983 Phase II Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread (CheckMate 9X8) Active, not recruiting USA | ESP | CAN 2
NCT04310176 Phase II Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab + Capecitabine Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil Bevacizumab + Fluorouracil + Valproic acid Bevacizumab + Capecitabine + Valproic acid Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + Valproic acid Bevacizumab + Capecitabine + Oxaliplatin + Valproic acid Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer (REVOLUTION) Recruiting ITA 0
NCT02141295 Phase II Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin RO5520985 Bevacizumab + Fluorouracil + Leucovorin Fluorouracil + Leucovorin + RO5520985 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE) Terminated USA | FRA | ESP | BEL | AUT 2
NCT01212822 Phase II Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer Completed USA 0
NCT03186326 Phase II Aflibercept + Fluorouracil + Irinotecan + Leucovorin Aflibercept + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin + Panitumumab Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Avelumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (SAMCO) Active, not recruiting FRA 0
NCT02563002 Phase III Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Pembrolizumab Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) Active, not recruiting 0
NCT04595266 Phase II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + unspecified EGFR antibody Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + unspecified EGFR antibody Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease (LIVERPEARL) Recruiting ESP 0
NCT04952753 Phase II Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NIS793 Bevacizumab + Fluorouracil + Leucovorin + NIS793 + Oxaliplatin Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC (daNIS-3) Recruiting USA | ITA | FRA | ESP | DEU | CAN 7
NCT01442935 Phase II Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases Completed FRA 0
NCT03117972 Phase II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Capecitabine Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels (CLavSyn) Recruiting FRA 0
NCT03828227 Phase III Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin Bevacizumab + Capecitabine Quality of Life in Elderly Patients With Metastatic Colorectal Cancer Receiving First-line Therapy Based on Simplified Geriatric Parameters (COLAGE) Recruiting FRA 0
NCT01622543 Phase II Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Pelareorep Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer Completed CAN 0
NCT02162563 Phase III Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin + Panitumumab Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases (CAIRO5) Recruiting BEL 1
NCT03635021 Phase III Fluorouracil + Irinotecan + Leucovorin + Panitumumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer (CR-SEQUENCE) Active, not recruiting ESP 0
NCT03750786 Phase III Arfolitixorin + Bevacizumab + Fluorouracil + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT) Active, not recruiting USA | FRA | ESP | DEU | CAN | AUT 4


Additional content available in CKB BOOST